Rick Austin
Company: Harpoon Therapeutics
Job title: Vice-President Research
Seminars:
Tritac-XR: An Extended-Release T Cell Engager Platform Designed to Minimize Cytokine Release Syndrome 5:00 pm
Explore how T cell engagers are potent drugs, but their development can be hindered by cytokine release syndrome (CRS) Understand how TriTAC-XR molecules are engineered T cell engager prodrugs that become slowly activated by proteases in circulation Assess how TriTAC-XR’s extended-release mechanism reduces cytokine levels in cynomolgus monkey while generating pharmacodynamic effects comparable to a…Read more
day: Day One
Panel Discussion: Assessing Past Progress Successes with Various Targets 4:30 pm
HER2, PSMA, EPCAM, and CEA antigens present therapeutic opportunity: which of these presents as the most realistic option? Assess the cleanness of these antigen targets Highlight key strategies that can be leveraged to identify the cleanest targetsRead more
day: Day One